Last month, the New York Times reported on a Texas breast cancer patient who took a genetic test to see if she also had an increased risk for ovarian cancer. Before she had the surgery to remove her ovaries, the patient asked for a second opinion and found no other test was available. The development of a second test was blocked, in part, to a gene patent held by Myraid. The patient filed a lawsuit against Myriad and the Patent Office, challenging the USPTO decision to grant a patent on a gene to Myriad. The lawsuit, organized by the ALCU, claims that the issue is not only a question of patent law, but of the First Amendment. Read the story here.